Introduction
Acute myeloid leukemia (AML) is a genetic disorder characterized by accumulation of abnormal myeloid progenitor cells in the bone marrow, resulting in hematopoietic failure (Robak and Wierzbowska, 2009) . AML is commonly associated as a disease of the elderly, with the majority of patients dying with the condition. (Kupsa et al., 2012) . Standard treatment options for AML are chemotherapy and hematopoietic stem cell transplantation (Robak and Wierzbowska, 2009; Smits et al., 2009) . The majority of patients with AML does not achieve complete remission (CR) or are expected to relapse even with intensive chemotherapy. This is mainly due to the development of drug resistance in tumor cells (Xiao et al., 2009; Kupsa et al., 2012; Szer, 2012) . In addition, owing to the occurrence of relapse and development of graft-versus-host-disease (GVHD) 
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cell transplantation, the treatment of these patients is still controversial (Robak and Wierzbowska, 2009; Smits et al., 2009) . Therefore, the design of new therapeutic strategies using less toxic and more specific agents is necessary.
Dysregulation of the apoptosis (Programmed cell death) machinery contributes to the formation of neoplasia and subsequent resistance to chemotherapy (Zhang et al., 2012; Li et al., 2013) . As most of the chemotherapy agents exert their anti-tumor effects by triggering apoptosis, new approaches for cancer treatment have focused on targeting mediators of this pathway (High et al., 2010; Akagi et al., 2013) .
Myeloid cell leukaemia-1 (Mcl-1), a highly regulated member of the anti-apoptotic B-cell lymphoma-2 (Bcl-2) family of proteins, was initially founded in the ML-1 human myeloid leukemia cell line during differentiation (Kozopas et al., 1993) . This protein is expressed in different tissue and tumor cells and possesses an important role in the control of apoptosis and cell cycle program. Moreover, some reports have indicated that Mcl-1 is needed for the function of hematopoetic cell systems and survival of tumor cells (Brunelle et al., 2009; Yecies et al., 2010; Glaser et al., 2012) . Studies have shown that Mcl-1 is overexpressed in various malignancies and downregulation of this protein by antisense oligonucleotide (ASO) or RNA interference (RNAi) technology induced apoptosis and sensitized tumor cells to anti-cancer agents (Chetoui et al., 2008; Skoda et al., 2008; Warr and Shore, 2008; Quinn et al., 2011; Akagi et al., 2013) . Moreover, elevated expression of Mcl-1 at the time of leukemic relapse, offers a possible explanation to the role of this protein in the survival of leukemia cells after chemotherapy (Kaufmann et al., 1998) .
In this study, we investigated whether suppression of Mcl-1 by small interference RNA (siRNA) could sensitize HL-60 human AML cell line to chemotherapeutic agent etoposide. We therefore examined the effects of either Mcl-1 specific siRNA (siMcl-1) or etoposide alone, versus their combination treatment in promoting tumor cells apoptosis.
Materials and Methods
Cell culture conditions
The HL-60 leukemic cells (Pasteur Institute, Tehran, Iran) were maintained in RPMI-1640 culture medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (SigmaAldrich), 1% antibiotics (100 IU/ml penicillin, 100 µg/ ml streptomycin) (Sigma-Aldrich), 2 mM of glutamine, and 1% sodium pyruvate at 37°C in 95% humidified atmosphere containing 5% CO 2 . The cells were subcultured with an initial concentration of 5 × 10 4 cells/ ml and used in the logarithmic growth phase in whole experiments.
Transfection of siRNA
The Mcl-1 siGENOME siRNA and a negative control (NC) siRNA were ordered from Dharmacon (Lafayette, CO, USA). Just before transfection, HL-60 cells were cultured in RPMI-1640 medium without FBS and antibiotics. Transfection of siRNAs was performed using Lipofectamine™2000 reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. In brief, siRNAs (at a final concentration of 80 nM) and lipofectamine (4 µl/ml of transfection medium) were diluted in Opti-MEM I medium (Invitrogen) separately and mixed gently. After incubation for 15 min at ambient temperature, the diluted solutions were combined and incubated for another 15 min at ambient temperature. Following on, the complexes were then added to the culture medium. Treatment with only lipofectamine was considered as siRNA blank control. After 6 h incubation of the cells at 37˚C in a humidified CO 2 incubator, RPMI medium plus FBS was added to a final FBS concentration of 10%, with cells being cultured under the same conditions. For assessment of effective gene silencing, transfection (5 × 10 5 cells/well) was performed in 6-well culture plates. After 24, 48 and 72 h, down-regulation of Mcl-1 was monitored by real-time quantitative PCR (RTqPCR) and Western blotting.
Cytotoxicity assay
The effect of siMcl-1 on the sensitivity of HL-60 cell line to etoposide (Sigma-Aldrich) was evaluated using 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) assay. The experiment was divided into eight groups: etoposide, siMcl-1, NC siRNA, siMcl-1 and etoposide, NC siRNA and etoposide, siRNA blank control, etoposide blank control and combination blank control. Briefly, cells were cultivated at a density of 2 × 10 4 cells/well in 96-well tissue culture plates. Six hours after transfection, the cells were treated with various concentrations of etoposide (0.001, 0.2, 0.5, 1, 2 and 4 µM). Cells treated with only 1% DMSO, solvent of etoposide, were served as etoposide blank controls. Also, treatment with a mixture of 1% DMSO and lipofectamine without siRNA were considered as a combination blank control. After 18 h of incubation, the cytotoxicity of the treatments was determined using a cell proliferation MTT kit (Roche Diagnostics GmbH, Mannheim, Germany) as described by the manufacturer. The absorbance (A) of the formazan dye was quantified with an ELISA plate reader (Awareness Technology, Palm City, FL, USA) at 570 nm with a reference wavelength of 650 nm. The survival rate (SR) was calculated from the following formula: SR (%) = (A Test /A Control) ×100%. IC 50 (concentration that produced 50% cytotoxicity) values were determined using Prism 6.01 software (GraphPad Software Inc., San Diego, CA, USA).
Combination effect analysis
The effect of the interaction between siMcl-1 and etoposide was determined using the value of the coefficient of drug interaction (CDI), based on the Chou-Talalay method (Chou and Talalay, 1984; Han et al., 2013) . The CDI was calculated using the following equation: CDI = AB/ (A×B), where AB is the survival rate of the combination group relative to the control group, A and B are the survival rate of siMcl-1 and etoposide relative to the corresponding control group. CDI > 1, CDI = 1 and CDI < 1 indicate antagonistic, additive and synergistic effects, respectively.
Cell viability assay
The effect of siMcl-1 on cell growth was measured by the trypan blue exclusion assay. HL-60 cells (4 × 10 4 cells/ well) were transfected with siRNAs in 24-well culture plates and incubated for 24-120 h. At indicated time points, the cells were harvested and cell suspensions stained with equal volume of 0.4% trypan blue (Merck KGaA, Darmstadt, Germany). After 3 min of incubation, the number of viable cells (unstained blue) was counted under an inverted microscope (Nikon Instrument Inc., Melville, NY, USA) using a hemocytometer. The percentage of viable cells was determined by dividing the number of viable cells in test group by the number of viable cells in blank control group and multiplying by 100. Also, the viability of the blank control group in each time was considered as 100%. DOI:http://dx.doi.org/10.7314/APJCP.2014.15.2 
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RT-qPCR
Following treatments, total RNA was isolated from the cells using AccuZolTM reagent (Bioneer, Daedeokgu, Daejeon, Korea) according to the manufacturer's protocol. Then, 1 µg of total RNA was reverse transcribed into complementary DNA (cDNA) by use of MMLV reverse transcriptase and oligo-dT primer following the manufacturer's instructions (Promega, Madison, WI, USA). Relative gene expression was quantified by RTqPCR using SYBR Premix Ex Taq (Takara Bio, Otsu, Shiga, Japan) and the Rotor-GeneTM 6000 system (Corbett Life Science, Mortlake, NSW, Australia). The PCR was performed in a 20 µl reaction system containing 1 µl of cDNA template, 12 µl of SYBR green reagent, 0.2 µM of each of the primers and 6 µl of nuclease-free distilled water. The sequences of PCR primers were as follows: forward, 5'-TAAGGACAAAACGGGACTGG-3', reverse, 5'-ACCAGCTCCTACTCCAGCAA-3', for Mcl-1, and forward, 5'-TCCCTGGAGAAGAGCTACG-3', and reverse, 5'-GTAGTTTCGTGGATGCCACA-3', for β-actin. The PCR conditions for Mcl-1 and β-actin 
Western blot analysis
Cells were collected, washed twice with cold phosphate-buffered saline (PBS) and resuspended in lysis buffer (1% Triton X-100, 1% SDS, 150 nM NaCl, 50 mM Tris-HCl, pH 7.4 and 1mM EDTA, pH 8) containing protease inhibitor cocktail complete (Roche Diagnostics GmbH). After 30 min of incubation on ice, the suspensions were centrifuged at 14,000 rpm for 10 min at 4°C and the supernatants were collected. Protein concentrations were measured by Bradford reagent (Sigma-Aldrich). Equal amounts of each protein sample (50 µg) were separated by 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidine diflouride membranes (PVDF) (GE Healthcare, Amersham, Buckinghamshire, UK).
The membranes were incubated at room temperature for 45 min in blocking buffer (3% fat-free milk and 0.05% Tween-20 in PBS) and then probed overnight at 4˚C with primary mouse monoclonal antibodies specific for Mcl-1 (1:500, Abcam, Cambridge, MA, UK) and β-actin (1:1,000, Abcam) diluted in 3% fat-free milk in PBS. Following three 5 min washes with PBS containing 0.05% Tween-20, membranes were incubated with corresponding horseradish peroxidase (HRP)-linked goat anti-mouse secondary antibody (1:3,000, Abcam) diluted in PBS for 2 h at room temperature. Next, the membranes were washed again and bound antibodies visualized using enhanced chemiluminescence plus western blotting detection Kit (GE Healthcare) and X-ray film (Estman Kodak, Rochester, NY, USA). Densitometry was performed by ImageJ software (National Institues of Health, Bethesda, Maryland, USA) and the signal intensity of each protein band was normalized for the respective actin loading control.
Apoptosis ELISA assay
Cell death was quantified with a cell death detection ELISA plus kit (Roche Diagnostics GmbH) that measures mono-and oligonucleosomes released into the cytoplasm of apoptotic cells. The HL-60 cells were seeded at a density of 4 × 10 4 cells/well in 24-well plates and treated with siMcl-1, NC siRNA, the IC 50 dose of etoposide or a combination of the two, as described previously. Twenty-four hours after transfection, cells were harvested and ELISA assay was performed according to the manufacturer's protocol. In brief, the cell lysates were obtained and centrifuged at 200 g for 10 min. Twenty microliters of the supernatants and 80 µl of immunoreagent containing anti-histone-biotin and anti-DNA-peroxidase were then transfered to each well of a streptavidin-coated plate and the plate was incubated for 2 h in 25°C. The wells were washed with incubation buffer and 100 µl of 2, 2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) solution was added. The reactions were stopped with ABTS stop solution and absorbance was measured using an ELISA plate reader at 405 nm (with a reference wavelength of 490 nm). Results were expressed as the fold increase in the absorbance of treatment groups relative to the blank control group.
Statistical analysis
Data were presented as mean ± standard deviation (SD). Analysis of variance (ANOVA) followed by Bonferroni's test was used to determine the significant differences between groups. Values of P less than 0.05 were considered significant. All statistical analyses were performed using GraphPad Prism software.
Results
BsiRNA down-regulated Mcl-1 mRNA and protein levels in HL-60 cells
Firstly, we examined the effect of siRNA on Mcl-1 gene expression in tumor cells by RT-qPCR and Western blotting. Relative gene expression was calculated in relation to the blank control, which was considered as 100%. Compared with the blank control, treatment with siMcl-1 markedly reduced Mcl-1 mRNA and protein Figure 2B ) (p<0.05). Notably, treatment with NC siRNA had minimal effect on mRNA and protein levels compared with the blank control (p>0.05).
Down-regulation of Mcl-1 inhibited cell growth
As overexpression of Mcl-1 is associated with survival of leukemic cells; we therefore sought to examine whether down-regulation of this protein could inhibit the growth of HL-60 cells. The cells were transfected with siMcl-1 and NC siRNA. Cell viability was then determined every 24 h for 5 days by trypan blue assay. In our study, the cell growth curve showed that compared with blank control group, siMcl-1 significantly reduced cell viability in a time dependent manner (p<0.05; Figure 3 ). Beginning at 24 h after transfection of Mcl-1 siRNA, the cell viability decreased rapidly to 76.68% and dropped to 39.23% on day 5. In contrast, no significant differences in cell viability were found between the NC siRNA transfected cells and the blank control group (p>0.05; Figure 3 ).
siMcl-1 increased sensitivity to etoposide in a synergic manner
To analyze whether reduced Mcl-1 expression could enhance the sensitivity of HL-60 cells to etoposide, a combination treatment with siMcl-1 and etoposide was performed. As shown in Figure 4 , single treatment with etoposide induced cytotoxicity in a dose-dependent manner. The results showed that siMcl-1 alone significantly lowered the cell survival rate to 68.32%, relative to the blank control (p<0.05). Furthermore, combination therapy further reduced the cell survival rate compared with siMcl-1 or etoposide monotreatment (p<0.05). The IC 50 value of etoposide drastically decreased from 2.03 µM to 1.01 µM in the presence of siMcl-1. The combination effects of siMcl-1 and etoposide were also synergistic with siRNAs and etoposide alone or in combination. Twentyfour hours after transfection, apoptosis was detected by cell death ELISA assay as described previously. The data represent mean±SD (n=3); *p<0.05 versus blank control; #p<0.05 :http://dx.doi.org/10.7314/APJCP.2014.15.2 
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with the CDI values of less than 1 in all concentrations of etoposide (Figure 4) . Meanwhile, NC siRNA had an insignificant effect on the chemosensitivity of the cells compared with etoposide alone (p>0.05; Figure 4 ).
Down-regulation of Mcl-1 enhanced etoposide-induced apoptotic cell death
To confirm whether the observed synergistic cytotoxic effects between siMcl-1 and etoposide were related to the increase in the extent of apoptosis, the effects of specific siRNA and etoposide alone and in combination on apoptosis, were examined using an ELISA-based cell death detection system. Figure 5 , demonstrates that treatment of leukemia cells with siMcl-1 or etoposide alone significantly increased apoptosis by 9.58 and 19.70 fold, respectively, compared to the blank control. Moreover, combination treatment further enhanced apoptosis to 25.16 fold (p<0.05). On the other hand, treatment with NC siRNA alone or in combination with etoposide displayed no distinct alterations in the extents of apoptosis relative to the blank control or etoposide monotreatment, respectively (p>0.05). Therefore, we concluded that the chemosensitization effect of Mcl-1 down-regulation is partially attributed to the enhancement of apoptosis.
Discussion
Despite intensive efforts in the treatment of AML, it is unfortunately still deemed as an incurable disease with a high mortality rate. Owing to the occurrence of chemoresistance in leukemia cells, the majority of patients does not achieve CR or show relapse after first CR, following the standard therapy (Smits et al., 2009; Xiao et al., 2009; Szer, 2012) . Therefore, development of new strategies for improved therapy is required. It has been shown that Mcl-1 up-regulates in a variety of malignancies, such as leukemia (Warr and Shore, 2008) . On the contrary, others have demonstrated that downregulation of Mcl-1 can sensitize cancer cells to anti-tumor agents (Chetoui et al., 2008; Skoda et al., 2008) . The above reports indicate that Mcl-1 is linked to drug resistance and may be an appropriate target for chemosensitization of tumor cells. However, the effect of Mcl-1 depletion on sensitivity of AML cells to the chemotherapeutic agent etoposide has yet to be investigated. Thus, we examined a gene therapy strategy using siMcl-1 in combination with etoposide on HL-60 leukemia cell line.
RT-qPCR and Western blot revealed that treatment with siMcl-1 led to steady decrease in the expression of Mcl-1 at the mRNA and protein levels over a 3-day period. These results suggest that siMcl-1 effectively blocked the translation of the Mcl-1 protein through cleavage of the corresponding mRNA. The results of the cell viability assay indicated that the down-regulation of Mcl-1 significantly decreased the viability of cells compared with the blank control group during a 5-day period. These results show that Mcl-1 may play a critical role in the survival and growth of leukemia cells. The MTT assay findings demonstrated that pretreatment with siMcl-1 synergistically enhanced the cytotoxicity of etoposide in HL-60 cells, and the IC 50 value was subsequently decreased substantially. Therefore, it is proposed that down-regulation of Mcl-1 could sensitize HL-60 cells to etoposide.
To further investigate the role of Mcl-1 in the chemoresistance of tumor cells, we examined the effect of Mcl-1 down-regulation on etoposide-induced apoptosis. ELISA cell death assay showed that the chemotherapeutic agent etoposide, alone, caused remarkable apoptosis in leukemia cells. Of note, we found that the inhibition of Mcl-1 using siRNA also resulted in significant apoptosis in the absence of etoposide, which is in contrast to the finding of others on solid tumors (Thallinger et al., 2003 , Thallinger et al., 2004 . However, this observation is similar to that found on other studies on hematological malignancies (Hussain et al., 2007; Quinn et al., 2011) , illustrating the important biological role of Mcl-1 in leukemic cells. In addition, siMcl-1, in combination with etoposide dramatically enhanced apoptosis compared with siRNA alone or etoposide alone. In contrast, neither NC siRNA nor lipofectamine treatment changed the impact of chemotherapy, which supports the specific effect of siMcl-1. These results are in agreement with previous reports using other tumor cells (Kano et al., 2009 , Akagi et al., 2013 . The above-mentioned results confirm that the presence of anti-apoptotic Mcl-1 protein is required for the survival and development of chemoresistance in the HL-60 cell line. Thus, targeting of this protein could induce apoptosis and sensitize tumor cells to chemotherapy agents.
Apoptosis can be initiated through two major signaling pathways: the intrinsic, mitochondrial pathway and the extrinsic, death receptor pathway (Warr and Shore, 2008) . Mcl-1 mainly inhibits the intrinsic pathway by the sequestering and neutralization of pro-apoptotic Bcl-2 family members such as Bak, Bax and Bim, thereby preserving mitochondria integrity. This action blocks the release of cytochrome c from the inner mitochondrial membrane space that is required for caspase activation and next apoptotic events (Warr and Shore, 2008; Zhang et al., 2012; Akagi et al., 2013) . Recent studies on melanoma cells have indicated that up-regulation of Mcl-1 inhibited the death receptor pathway of apoptosis (Chetoui et al., 2008; Boisvert-Adamo et al., 2009 ). However, the exact role of Mcl-1 in the regulation of the extrinsic pathway of leukemic cells is not clear. Etoposide is a potent cytotoxic agent that induces apoptosis by stabilizing a covalent DNA topoisomerase II-DNA complex, causing DNA doublestrands to break. In addition, it was shown that treatment of HL-60 cells with etoposide triggers both intrinsic and extrinsic pathways of apoptosis by activation of different caspases (Martins et al., 1997; Montecucco and Biamonti, 2007) . Our study demonstrates that suppression of Mcl-1 protein induces apoptosis and augments the effect caused by etoposide. However, the precise molecular mechanisms of the sensitization remain unclear and further investigations are needed.
RNAi or post-transcriptional gene silencing is a powerful strategy for the knockdown of a specific gene in which double-stranded RNA (called siRNA) is introduces to the cells and suppresses gene expression through cleavage of the related messenger RNA (mRNA). Due to advantages of RNAi such as its efficacy, specificity, and low cytotoxicity, this phenomenon is extensively used in gene therapy studies (Yang and Mattes, 2008; David et al., 2010; Shan, 2010; Ramachandran and Ignacimuthu, 2012) . In comparison of the antisense oligonucleotide technology, siRNA has several advantages such as a greater resistance to nuclease-induced degradation (Reischl and Zimmer, 2009; Kanasty et al., 2012) . In contrast, transient nature of chemically synthesized siRNA is one of the most important limitations of siRNA-based therapeutics. The use of constitutive siRNA-based vector systems with higher efficacy may overcome this drawback, especially for long term in vivo studies (Yang and Mattes, 2008; David et al., 2010; Shan, 2010) .
Together, we have demonstrated that Mcl-1 plays a pivotal role in the survival and resistance of HL-60 cells to etoposide. Specific down-regulation of Mcl-1 by siRNA induced significant apoptosis in leukemia cells in vitro. Most importantly, the combination of etoposide with siMcl-1 showed synergistic anti-tumor effect. Our data underline the potential of siMcl-1 for apoptosis induction and sensitization of leukemia cells to anti-tumor drugs. This phenomenon appears to decrease the serious sideeffects related to high-dose chemotherapy. Thus, our study suggests that the Mcl-1 gene can be considered as an attractive target in gene therapy for AML patients and may be a novel strategy to overcome chemoresistance in the future.
